Myeloid Therapeutics To Participate In Barclays Biotech: 1X1 Private Company Symposium

2024-08-01 04:19:02

(MENAFN- PR Newswire) CAMBRIDGE, Mass., Aug. 1, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the Barclays Biotech: 1x1 Private Company Symposium on Wednesday, August 7, 2024.

This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors.

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage immunology company,
engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.

For additional information, please visit,

and follow us on
LinkedIn
and
X/Twitter . For collaborative interests, write to [email protected] .

Investor Contact
Amy Conrad
Juniper Point
[email protected]

SOURCE Myeloid Therapeutics

MENAFN01082024003732001241ID1108508274

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.